Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences (NASDAQ:SLDB) filed a routine Form 4 disclosing that director Georgia Keresty received a stock-option grant covering 77,500 shares on 06/12/2025 at an exercise price of $4.58 per share.
The option vests in full on the earlier of the one-year anniversary of the grant or immediately prior to the next annual shareholder meeting, and accelerates upon certain change-in-control events. It expires on 06/12/2035. No open-market purchases or sales of common stock were reported, and Keresty’s beneficial ownership now reflects only the newly granted option, held directly.